Immunosuppressant access for the treatment of ICI adverse events

Have your say on a critical issue affecting immunotherapy patients across the UK.

The IOCN and UKSACT Board have written to NHS England raising concerns about inequitable access to funding for immunosuppressive medicines used to manage immune checkpoint inhibitor (ICI) toxicities.

A meeting with NHS England is planned for late November to discuss this critical issue, and we need your input to ensure the voice of the UK immunotherapy community is heard.

Despite international guidance and real-world evidence supporting the use of biologic and JAK inhibitor therapies in managing immune-related adverse events (irAEs), access across the UK remains inconsistent—leading to significant geographical inequalities and patient risk.

Your experience is vital to shaping national policy discussions.

Please complete the IOCN survey to help us understand the scale of the challenges and the treatment variation we as a community are experiencing and can only do that with your help.

Complete the survey here